Hawthorne, New York 10532


The objective of this study is to evaluate the potential of Topicort® (desoximetasone) Topical Spray, 0.25% to suppress hypothalmic pituitary adrenal axis function. The secondary objectives are to evaluate the efficacy parameters, pharmacokinetics and adverse event profile.

Study summary:

An open label, post marketing safety study to assess the potential of a TOPICORT® (desoximetasone) Topical Spray, 0.25% to suppress HPA axis function following twice daily dosing for 28 days.


Inclusion Criteria: - Patients aged 7 years and older must have provided written assent accompanied by written informed consent from patient's representative - Clinical diagnosis of stable plaque psoriasis with involvement of ≥ 10% body surface area (excluding face and scalp) - Physicians Global Assessment score of 3 or 4 at baseline Exclusion Criteria: - Has other dermatological conditions that may interfere with clinical assessments - Allergy or sensitivity to corticosteroids or any drug hypersensitivity or intolerance that would compromise patient safety or study results - History of an adverse reaction to Cortrosyn™ or similar test reagents - Chronic infectious disease, system or organ disorder or other medical condition that would place patient at undue risk by study participation



Primary Contact:

Study Chair
Novum Pharmaceutical Research Services

Taro Pharmaceuticals U.S.A. Inc.
Phone: +1 914-345-900

Backup Contact:


Location Contact:

Hawthorne, New York 10532
United States

Natalie Yantovskiy

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: October 18, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.